Complete Genomics is a life sciences company that has developed and commercialized a deoxyribonucleic acid sequencing platform for whole human genome sequencing and analysis. Co.'s Complete Genomics Analysis Platform Platform, combines its human genome sequencing technology with its informatics and data management software and its outsourced service model to provide its customers with data that is ready to be used for genome-based research. Co. sells its whole human genome sequencing service through its direct field sales and support organizations. The GNOM stock yearly return is shown above.
The yearly return on the GNOM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GNOM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|